vinorelbine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vinca alkaloids 2827 71486-22-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vinorelbin ditartrate
  • noranhydrovinblastine tartrate
  • vinorelbine
  • navelbin
  • navelbine base
  • 5'-anhydrovinblastine
  • vinorelbine tartrate
  • vinorelbine ditartrate
  • navelbine
  • vinorelbine base
A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES.
  • Molecular weight: 778.95
  • Formula: C45H54N4O8
  • CLOGP: 5.94
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 2
  • TPSA: 133.87
  • ALOGS: -4.81
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.00 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 11 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.936 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 112.720 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.435 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 8.072 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 15.130 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 25.750 % Moderate 0.73
herg hERG pIC50 4.698 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 4.732 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 69.024 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 21.400 % Moderate 0.73
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 57.677 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 30.409 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 14.622 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 11.860 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 50.816 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.78
pppb Pig plasma protein binding (% unbound) 25.790 % Moderate 0.73
rat-kpuu-brain Rat brain Kpuu 0.012 % High 1
rh-clint Rat hepatocyte intrinsic clearance 5.943 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 32.070 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 14.180 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 620.869 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1994 FDA PIERRE FABRE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1068.13 23.75 510 20280 106360 90501297
Disease progression 1012.30 23.75 557 20233 156058 90451599
Metastases to bone 538.02 23.75 207 20583 25298 90582359
Metastases to liver 527.42 23.75 211 20579 28596 90579061
Neutropenia 471.71 23.75 399 20391 224505 90383152
Palmar-plantar erythrodysaesthesia syndrome 426.96 23.75 180 20610 27843 90579814
Metastases to lung 384.96 23.75 143 20647 15848 90591809
Breast cancer metastatic 377.82 23.75 139 20651 14993 90592664
Metastases to central nervous system 375.66 23.75 144 20646 17398 90590259
Metastases to lymph nodes 369.87 23.75 128 20662 11561 90596096
Neoplasm progression 261.15 23.75 149 20641 44337 90563320
Mucosal inflammation 237.81 23.75 154 20636 57471 90550186
Febrile neutropenia 220.66 23.75 224 20566 158125 90449532
Neuropathy peripheral 196.72 23.75 197 20593 136773 90470884
Pleural effusion 173.66 23.75 168 20622 111823 90495834
Osteonecrosis of jaw 147.89 23.75 99 20691 39004 90568653
Metastases to skin 145.40 23.75 42 20748 2098 90605559
Myelosuppression 143.58 23.75 110 20680 53481 90554176
Haematotoxicity 137.54 23.75 64 20726 12471 90595186
Breast cancer recurrent 127.95 23.75 48 20742 5455 90602202
Metastases to peritoneum 125.61 23.75 44 20746 4111 90603546
Ascites 117.05 23.75 93 20697 47647 90560010
PIK3CA-activated mutation 115.64 23.75 31 20759 1173 90606484
Ejection fraction decreased 112.77 23.75 72 20718 26181 90581476
Thrombocytopenia 110.68 23.75 183 20607 208542 90399115
Polyneuropathy 98.18 23.75 59 20731 19282 90588375
Breast cancer 97.40 23.75 88 20702 53673 90553984
Streptococcal sepsis 97.14 23.75 35 20755 3549 90604108
Anaemia 89.60 23.75 228 20562 352574 90255083
Tonsillar disorder 87.97 23.75 25 20765 1177 90606480
Carbohydrate antigen 15-3 increased 87.50 23.75 28 20762 1979 90605678
Pseudomonal sepsis 87.36 23.75 34 20756 4268 90603389
Joint swelling 83.77 23.75 9 20781 503291 90104366
Nail bed inflammation 82.12 23.75 26 20764 1775 90605882
Nasal mucosal disorder 81.34 23.75 26 20764 1831 90605826
Neurotoxicity 80.30 23.75 54 20736 21413 90586244
Paronychia 79.00 23.75 38 20752 7968 90599689
Off label use 77.91 23.75 474 20316 1101778 89505879
Death 77.19 23.75 255 20535 456296 90151361
Metastases to pleura 74.89 23.75 25 20765 2019 90605638
Blood uric acid decreased 72.75 23.75 20 20770 833 90606824
Vascular device infection 72.68 23.75 41 20749 11911 90595746
Cardiotoxicity 71.79 23.75 40 20750 11349 90596308
Leukopenia 71.24 23.75 101 20689 100609 90507048
Fall 69.93 23.75 13 20777 481797 90125860
Eosinophil percentage increased 69.33 23.75 20 20770 994 90606663
Bone marrow failure 66.89 23.75 57 20733 32164 90575493
Hepatotoxicity 65.82 23.75 66 20724 45776 90561881
Lymphangiosis carcinomatosa 63.45 23.75 21 20769 1651 90606006
Nasal disorder 63.26 23.75 25 20765 3267 90604390
Metastasis 63.20 23.75 30 20760 6107 90601550
Drug hypersensitivity 62.17 23.75 15 20775 463594 90144063
Metastatic neoplasm 60.42 23.75 27 20763 4788 90602869
Neutropenic sepsis 59.31 23.75 42 20748 18088 90589569
Arthralgia 59.18 23.75 55 20735 778467 89829190
Skin toxicity 57.42 23.75 29 20761 6750 90600907
Brain oedema 56.24 23.75 40 20750 17345 90590312
Maternal exposure during pregnancy 56.06 23.75 8 20782 360055 90247602
Disease recurrence 55.51 23.75 55 20735 37598 90570059
Diarrhoea 53.48 23.75 383 20407 938807 89668850
Nausea 53.33 23.75 435 20355 1109881 89497776
EGFR gene mutation 53.22 23.75 13 20777 337 90607320
Hyperchlorhydria 52.77 23.75 19 20771 1922 90605735
Sinusitis 52.53 23.75 8 20782 343080 90264577
Pancytopenia 51.41 23.75 96 20694 120167 90487490
Gastrointestinal toxicity 50.96 23.75 30 20760 9437 90598220
Abdominal discomfort 50.79 23.75 23 20767 477305 90130352
Pneumonitis 49.92 23.75 56 20734 44114 90563543
Osteonecrosis 49.58 23.75 44 20746 26197 90581460
Hepatic failure 49.47 23.75 53 20737 39675 90567982
Weight increased 47.91 23.75 18 20772 417909 90189748
Musculoskeletal stiffness 47.55 23.75 6 20784 296526 90311131
Varicose vein 46.91 23.75 26 20764 7301 90600356
Tumour marker increased 46.74 23.75 24 20766 5783 90601874
Hepatic enzyme increased 45.81 23.75 13 20777 360723 90246934
Pericarditis 44.46 23.75 5 20785 270146 90337511
Wound 44.30 23.75 8 20782 302972 90304685
Urticaria 44.15 23.75 9 20781 312725 90294932
Folate deficiency 43.76 23.75 19 20771 3146 90604511
Second primary malignancy 43.41 23.75 28 20762 10350 90597307
Candida infection 43.40 23.75 46 20744 34011 90573646
Pneumothorax 42.03 23.75 35 20755 19132 90588525
Therapy partial responder 41.72 23.75 37 20753 22006 90585651
Peripheral sensory neuropathy 41.29 23.75 26 20764 9224 90598433
Blister 41.27 23.75 5 20785 254993 90352664
Metastases to meninges 40.75 23.75 19 20771 3716 90603941
Metastases to chest wall 40.43 23.75 12 20778 659 90606998
Vessel puncture site bruise 40.32 23.75 11 20779 445 90607212
Mediastinum neoplasm 39.88 23.75 8 20782 80 90607577
Activated PI3 kinase delta syndrome 39.88 23.75 8 20782 80 90607577
Diffuse large B-cell lymphoma recurrent 38.66 23.75 18 20772 3508 90604149
Hormone receptor positive breast cancer 38.64 23.75 12 20778 769 90606888
Hiccups 38.07 23.75 17 20773 3009 90604648
Pruritus 37.94 23.75 41 20749 541484 90066173
Asthenia 37.72 23.75 230 20560 533521 90074136
Drug resistance 36.82 23.75 40 20750 30409 90577248
Blood lactate dehydrogenase increased 36.60 23.75 37 20753 25895 90581762
Bone pain 36.41 23.75 57 20733 61926 90545731
Blood creatinine decreased 36.00 23.75 21 20769 6494 90601163
Folliculitis 35.68 23.75 3 20787 204350 90403307
Joint neoplasm 35.56 23.75 7 20783 63 90607594
Postictal state 35.50 23.75 13 20777 1380 90606277
Superior vena cava syndrome 35.16 23.75 11 20779 722 90606935
Decreased appetite 35.13 23.75 175 20615 376365 90231292
Tumour pain 35.11 23.75 14 20776 1873 90605784
Restlessness 34.86 23.75 42 20748 35678 90571979
Metastases to spine 34.62 23.75 17 20773 3726 90603931
Injection site extravasation 34.47 23.75 23 20767 8996 90598661
Injury 34.17 23.75 3 20787 197346 90410311
Transaminases 34.04 23.75 7 20783 80 90607577
Skin fissures 33.68 23.75 32 20758 20777 90586880
Subclavian vein thrombosis 33.56 23.75 14 20776 2102 90605555
Exposure during pregnancy 33.36 23.75 7 20783 238403 90369254
Hypertransaminasaemia 32.85 23.75 28 20762 15797 90591860
Quadriplegia 32.84 23.75 14 20776 2217 90605440
Metastases to bone marrow 32.69 23.75 10 20780 609 90607048
Migraine 32.68 23.75 3 20787 190389 90417268
Cough 32.68 23.75 169 20621 368793 90238864
Arthropathy 32.63 23.75 22 20768 366220 90241437
Pituitary tumour 32.60 23.75 11 20779 918 90606739
Osteolysis 32.47 23.75 16 20774 3534 90604123
Soft tissue neoplasm 32.41 23.75 7 20783 103 90607554
Odynophagia 32.03 23.75 22 20768 9021 90598636
Swelling 31.30 23.75 30 20760 419028 90188629
Non-small cell lung cancer recurrent 31.13 23.75 7 20783 125 90607532
Nail infection 30.93 23.75 14 20776 2558 90605099
Dermatitis exfoliative generalised 30.83 23.75 18 20772 5575 90602082
Left ventricular dysfunction 30.54 23.75 26 20764 14643 90593014
Gene mutation 30.15 23.75 13 20777 2117 90605540
Acute myeloid leukaemia 30.14 23.75 30 20760 20610 90587047
Hypersensitivity 30.12 23.75 36 20754 454641 90153016
Metastases to soft tissue 30.04 23.75 8 20782 295 90607362
Vomiting 29.54 23.75 293 20497 788000 89819657
Constipation 29.53 23.75 135 20655 280260 90327397
Discomfort 29.49 23.75 13 20777 274322 90333335
Leukonychia 29.39 23.75 6 20784 66 90607591
Jaw operation 29.33 23.75 10 20780 861 90606796
Acquired gene mutation 29.16 23.75 11 20779 1268 90606389
Thrombocytopenic purpura 28.46 23.75 12 20778 1849 90605808
Lymphoedema 27.86 23.75 24 20766 13729 90593928
Wheezing 27.69 23.75 10 20780 238070 90369587
Condition aggravated 27.39 23.75 60 20730 595485 90012172
Pain 27.18 23.75 127 20663 996214 89611443
Mobility decreased 26.76 23.75 12 20778 250722 90356935
Sepsis 26.42 23.75 96 20694 179718 90427939
Gingival bleeding 26.20 23.75 24 20766 14879 90592778
Inflammation 25.48 23.75 5 20785 178587 90429070
Contusion 25.32 23.75 13 20777 251203 90356454
Invasive ductal breast carcinoma 25.31 23.75 18 20772 7800 90599857
Recurrent cancer 25.26 23.75 12 20778 2447 90605210
Poor peripheral circulation 24.99 23.75 14 20776 4011 90603646
Pyrexia 24.96 23.75 246 20544 660239 89947418
Treatment failure 24.81 23.75 20 20770 303908 90303749
Scintillating scotoma 24.77 23.75 6 20784 150 90607507
Primary mediastinal large B-cell lymphoma 24.75 23.75 5 20785 52 90607605
Nail avulsion 24.32 23.75 7 20783 345 90607312
Performance status decreased 24.19 23.75 14 20776 4266 90603391
Febrile bone marrow aplasia 23.91 23.75 19 20771 9719 90597938

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 268.53 24.75 191 5541 143465 42472138
Neutropenia 159.60 24.75 163 5569 199268 42416335
Malignant neoplasm progression 96.33 24.75 94 5638 108306 42507297
Febrile neutropenia 84.76 24.75 114 5618 185589 42430014
Neoplasm progression 81.64 24.75 50 5682 28950 42586653
Off label use 81.36 24.75 227 5505 638108 41977495
Interstitial lung disease 67.67 24.75 67 5665 78395 42537208
Myelosuppression 66.51 24.75 50 5682 40411 42575192
Haematotoxicity 61.88 24.75 30 5702 10955 42604648
Febrile bone marrow aplasia 60.98 24.75 29 5703 10152 42605451
Thrombocytopenia 59.64 24.75 98 5634 190181 42425422
Neutropenic sepsis 54.02 24.75 31 5701 15915 42599688
Pneumonitis 50.31 24.75 43 5689 41675 42573928
Retinopathy haemorrhagic 45.01 24.75 8 5724 71 42615532
Haematopoietic stem cell mobilisation 43.31 24.75 10 5722 352 42615251
Product use in unapproved indication 41.13 24.75 82 5650 184374 42431229
Agranulocytosis 39.88 24.75 33 5699 30579 42585024
Peripheral blood stem cell apheresis 39.58 24.75 8 5724 148 42615455
Metastases to the mediastinum 38.21 24.75 9 5723 346 42615257
Hyperfibrinogenaemia 35.59 24.75 7 5725 112 42615491
Pyrexia 34.85 24.75 124 5608 393918 42221685
Leukopenia 34.12 24.75 46 5686 74700 42540903
Toxic erythema of chemotherapy 33.26 24.75 7 5725 159 42615444
Diabetic ketoacidotic hyperglycaemic coma 32.39 24.75 7 5725 181 42615422
Metastases to central nervous system 32.07 24.75 19 5713 10336 42605267
Metastases to lung 30.35 24.75 19 5713 11405 42604198
Radiation pneumonitis 29.39 24.75 12 5720 2921 42612682
PIK3CA-activated mutation 29.05 24.75 6 5726 124 42615479
Disease recurrence 28.65 24.75 27 5705 29651 42585952
Bone marrow failure 26.17 24.75 27 5705 33066 42582537
Pancytopenia 25.78 24.75 52 5680 117691 42497912
Vena cava thrombosis 25.04 24.75 9 5723 1552 42614051
Acute myeloid leukaemia 24.91 24.75 22 5710 22234 42593369

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 835.53 20.23 549 21512 243485 110323753
Malignant neoplasm progression 753.21 20.23 455 21606 174112 110393126
Neutropenia 454.10 20.23 460 21601 374160 110193078
Metastases to central nervous system 327.56 20.23 135 21926 22682 110544556
Metastases to bone 326.88 20.23 148 21913 31224 110536014
Metastases to lung 316.04 20.23 132 21929 22931 110544307
Breast cancer metastatic 301.91 20.23 105 21956 11076 110556162
Metastases to lymph nodes 285.91 20.23 109 21952 14923 110552315
Neoplasm progression 281.99 20.23 170 21891 64425 110502813
Metastases to liver 270.81 20.23 135 21926 35251 110531987
Palmar-plantar erythrodysaesthesia syndrome 246.37 20.23 133 21928 40892 110526346
Febrile neutropenia 230.19 20.23 299 21762 316468 110250770
Myelosuppression 191.06 20.23 155 21906 94185 110473053
Neuropathy peripheral 175.49 20.23 197 21864 179080 110388158
Mucosal inflammation 169.90 20.23 146 21915 95995 110471243
Haematotoxicity 154.11 20.23 78 21983 21004 110546234
Osteonecrosis of jaw 125.86 20.23 92 21969 47925 110519313
Breast cancer recurrent 122.92 20.23 41 22020 3805 110563433
Metastases to skin 121.56 20.23 36 22025 2263 110564975
Thrombocytopenia 121.18 20.23 235 21826 348650 110218588
Neutropenic sepsis 119.02 20.23 75 21986 30671 110536567
Metastases to peritoneum 93.59 20.23 37 22024 5573 110561665
Off label use 92.37 20.23 561 21500 1499624 109067614
Streptococcal sepsis 90.07 20.23 35 22026 5037 110562201
Nasal mucosal disorder 88.82 20.23 27 22034 1856 110565382
Pleural effusion 87.99 20.23 140 21921 177569 110389669
Nail bed inflammation 86.82 20.23 27 22034 2003 110565235
Tonsillar disorder 86.13 20.23 25 22036 1464 110565774
Bone marrow failure 82.69 20.23 78 21983 57770 110509468
Ejection fraction decreased 82.34 20.23 67 21994 40813 110526425
PIK3CA-activated mutation 80.22 20.23 20 22041 653 110566585
Carbohydrate antigen 15-3 increased 80.21 20.23 24 22037 1563 110565675
Pneumonitis 79.78 20.23 87 21974 76444 110490794
Febrile bone marrow aplasia 76.23 20.23 46 22015 17419 110549819
Polyneuropathy 74.21 20.23 57 22004 31955 110535283
Vascular device infection 70.80 20.23 43 22018 16469 110550769
Paronychia 69.49 20.23 37 22024 11044 110556194
Pancytopenia 68.80 20.23 138 21923 209475 110357763
EGFR gene mutation 68.25 20.23 17 22044 553 110566685
Pseudomonal sepsis 67.65 20.23 34 22027 9012 110558226
Anaemia 62.68 20.23 245 21816 546841 110020397
Nasal disorder 60.55 20.23 25 22036 4209 110563029
Blood uric acid decreased 60.26 20.23 19 22042 1474 110565764
Disease recurrence 59.72 20.23 67 21994 60717 110506521
Eosinophil percentage increased 59.18 20.23 19 22042 1563 110565675
Therapy partial responder 58.84 20.23 53 22008 37008 110530230
Varicose vein 57.59 20.23 28 22033 6912 110560326
Joint swelling 56.70 20.23 10 22051 442835 110124403
Fall 56.30 20.23 25 22036 603457 109963781
Interstitial lung disease 55.94 20.23 100 21961 139234 110428004
Lymphangiosis carcinomatosa 54.48 20.23 20 22041 2462 110564776
Blood lactate dehydrogenase increased 54.41 20.23 55 22006 44279 110522959
Hepatotoxicity 54.11 20.23 65 21996 63335 110503903
Acute myeloid leukaemia 53.72 20.23 51 22010 38059 110529179
Nausea 53.19 20.23 424 21637 1235266 109331972
Drug hypersensitivity 52.48 20.23 13 22048 454077 110113161
Leukopenia 52.48 20.23 101 21960 148690 110418548
Hyperchlorhydria 49.55 20.23 18 22043 2151 110565087
Neurotoxicity 49.33 20.23 51 22010 42156 110525082
Arthralgia 49.04 20.23 50 22011 779582 109787656
Metastasis 47.37 20.23 26 22035 8241 110558997
Breast cancer 45.81 20.23 47 22014 38495 110528743
Metastases to the mediastinum 44.48 20.23 13 22048 780 110566458
Musculoskeletal stiffness 44.11 20.23 3 22058 279819 110287419
Hormone receptor positive breast cancer 43.88 20.23 12 22049 565 110566673
Metastatic neoplasm 43.70 20.23 22 22039 5851 110561387
Cardiotoxicity 43.44 20.23 32 22029 16849 110550389
Product use in unapproved indication 43.05 20.23 190 21871 447187 110120051
Agranulocytosis 42.68 20.23 57 22004 61703 110505535
Gastrointestinal toxicity 42.65 20.23 27 22034 11121 110556117
Abdominal discomfort 40.52 20.23 14 22047 393844 110173394
Vessel puncture site bruise 40.37 20.23 11 22050 511 110566727
Peripheral sensory neuropathy 39.31 20.23 30 22031 16650 110550588
Retinopathy haemorrhagic 39.14 20.23 8 22053 103 110567135
Pyrexia 38.95 20.23 309 21752 897956 109669282
Diarrhoea 38.53 20.23 371 21690 1139134 109428104
Quadriplegia 38.36 20.23 18 22043 4109 110563129
Pneumothorax 38.31 20.23 41 22020 35244 110531994
Gene mutation 38.31 20.23 17 22044 3412 110563826
Subclavian vein thrombosis 38.07 20.23 16 22045 2816 110564422
Ascites 37.74 20.23 67 21994 92741 110474497
Haematopoietic stem cell mobilisation 37.61 20.23 10 22051 423 110566815
Therapeutic product effect decreased 37.42 20.23 3 22058 244313 110322925
Candida infection 37.38 20.23 47 22014 47962 110519276
Sinusitis 37.30 20.23 7 22054 296681 110270557
Folate deficiency 37.11 20.23 18 22043 4420 110562818
Brain oedema 37.10 20.23 38 22023 31060 110536178
Metastases to spine 36.81 20.23 19 22042 5324 110561914
Joint neoplasm 36.54 20.23 7 22054 63 110567175
Peripheral blood stem cell apheresis 36.28 20.23 8 22053 151 110567087
Wound 35.57 20.23 3 22058 234434 110332804
Urticaria 35.17 20.23 10 22051 318847 110248391
Skin toxicity 34.12 20.23 24 22037 11759 110555479
Tumour pain 34.08 20.23 15 22046 2952 110564286
Non-small cell lung cancer recurrent 34.06 20.23 8 22053 202 110567036
Asthenia 33.75 20.23 244 21817 688755 109878483
Soft tissue neoplasm 33.38 20.23 7 22054 103 110567135
Nail infection 33.26 20.23 14 22047 2474 110564764
Invasive ductal breast carcinoma 32.92 20.23 19 22042 6627 110560611
Mediastinum neoplasm 32.60 20.23 7 22054 116 110567122
Cough 31.56 20.23 178 21883 461463 110105775
Sepsis 31.44 20.23 139 21922 327207 110240031
Skin fissures 31.22 20.23 31 22030 24427 110542811
Pituitary tumour 30.88 20.23 11 22050 1242 110565996
Radiation pneumonitis 30.87 20.23 16 22045 4520 110562718
Nail avulsion 30.43 20.23 7 22054 161 110567077
Primary mediastinal large B-cell lymphoma 30.31 20.23 6 22055 65 110567173
Pericarditis 30.18 20.23 4 22057 219110 110348128
Postictal state 30.16 20.23 13 22048 2433 110564805
Injection site extravasation 30.12 20.23 21 22040 10148 110557090
Drug resistance 30.07 20.23 46 22015 56328 110510910
Hyperfibrinogenaemia 30.06 20.23 7 22054 170 110567068
Maternal exposure during pregnancy 30.01 20.23 7 22054 254876 110312362
Blood creatinine decreased 29.74 20.23 20 22041 9117 110558121
Hypertransaminasaemia 29.59 20.23 30 22031 24225 110543013
Osteonecrosis 29.45 20.23 35 22026 33706 110533532
Transaminases 29.30 20.23 6 22055 78 110567160
Tumour marker increased 29.23 20.23 16 22045 5044 110562194
Hepatic enzyme increased 28.79 20.23 14 22047 320878 110246360
Acquired gene mutation 28.68 20.23 13 22048 2741 110564497
Leukonychia 27.91 20.23 6 22055 100 110567138
Weight increased 27.39 20.23 26 22035 419618 110147620
Restlessness 27.36 20.23 44 22017 56215 110511023
Non-small cell lung cancer 27.35 20.23 18 22043 7917 110559321
Jaw operation 26.98 20.23 9 22052 835 110566403
Diabetic ketoacidotic hyperglycaemic coma 26.90 20.23 7 22054 272 110566966
Poor peripheral circulation 26.28 20.23 14 22047 4183 110563055
Odynophagia 26.07 20.23 22 22039 14079 110553159
Malaise 25.93 20.23 60 22001 671759 109895479
Hepatic failure 25.88 20.23 48 22013 68691 110498547
Metastases to bone marrow 25.36 20.23 9 22052 1005 110566233
Osteolysis 25.27 20.23 15 22046 5508 110561730
Pulmonary embolism 25.25 20.23 97 21964 214377 110352861
Gingival bleeding 25.05 20.23 25 22036 19814 110547424
Metastases to chest wall 24.80 20.23 8 22053 668 110566570
Vomiting 24.80 20.23 284 21777 910391 109656847
Wheezing 24.68 20.23 10 22051 255220 110312018
Contusion 24.50 20.23 8 22053 233353 110333885
Thrombocytopenic purpura 24.43 20.23 12 22049 3027 110564211
Pain 24.34 20.23 103 21958 954852 109612386
Metastases to soft tissue 24.32 20.23 8 22053 711 110566527
Bone lesion 24.24 20.23 16 22045 7071 110560167
Toxic erythema of chemotherapy 24.20 20.23 7 22054 405 110566833
Scintillating scotoma 23.31 20.23 6 22055 223 110567015
Drug interaction 23.30 20.23 40 22021 500143 110067095
Second primary malignancy 23.24 20.23 23 22038 18045 110549193
Folliculitis 23.23 20.23 3 22058 167650 110399588
Discomfort 23.18 20.23 7 22054 214700 110352538
Condition aggravated 22.82 20.23 73 21988 734763 109832475
Neutrophil count decreased 22.60 20.23 64 21997 120877 110446361
Gastrointestinal bacterial infection 22.42 20.23 9 22052 1409 110565829
Pruritus 22.38 20.23 52 22009 581508 109985730
Onycholysis 22.35 20.23 11 22050 2788 110564450
Metastases to pleura 22.32 20.23 10 22051 2053 110565185
Hypothalamo-pituitary disorder 22.17 20.23 11 22050 2835 110564403
Xerophthalmia 22.13 20.23 8 22053 943 110566295
Dermatitis exfoliative generalised 22.12 20.23 18 22043 10954 110556284
Stress cardiomyopathy 21.98 20.23 21 22040 15785 110551453
Cardiac cirrhosis 21.91 20.23 6 22055 284 110566954
HRD gene mutation assay positive 21.77 20.23 4 22057 28 110567210
Left ventricular dysfunction 21.55 20.23 25 22036 23468 110543770
Primary mediastinal large B-cell lymphoma recurrent 21.22 20.23 5 22056 128 110567110
Feeling abnormal 21.19 20.23 5 22056 180706 110386532
Metastases to meninges 21.08 20.23 13 22048 5115 110562123
Diffuse large B-cell lymphoma recurrent 21.01 20.23 14 22047 6285 110560953
Cancer with a high tumour mutational burden 20.98 20.23 4 22057 35 110567203
Rash 20.62 20.23 89 21972 820875 109746363
Gastric neoplasm 20.61 20.23 6 22055 355 110566883
Abdominal neoplasm 20.44 20.23 7 22054 704 110566534
Vaccination site haemorrhage 20.41 20.23 4 22057 41 110567197
Swelling 20.38 20.23 24 22037 351017 110216221
Recurrent cancer 20.26 20.23 11 22050 3412 110563826

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01CA04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Vinca alkaloids and analogues
FDA CS M0022674 Vinca Alkaloids
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000972 Antineoplastic Agents, Phytogenic
MeSH PA D050256 Antimitotic Agents
MeSH PA D050257 Tubulin Modulators
FDA EPC N0000175612 Vinca Alkaloid
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:47868 photosensitizing agent

Related Drugs by ATC class:

L01CA Vinca alkaloids and analogues 5 drugs
vinblastinevincristinevindesinevinfluninevintafolide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Kaposi's sarcoma off-label use 109385007
Neoplasm of endometrium off-label use 123844007 DOID:1380
Small cell carcinoma of lung off-label use 254632001 DOID:5409
Metastatic Breast Carcinoma off-label use
Disorder of lung contraindication 19829001 DOID:850
Infectious disease contraindication 40733004
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Interstitial pneumonia contraindication 64667001
Intestinal obstruction contraindication 81060008 DOID:8437
Leukopenia contraindication 84828003 DOID:615
Gastrointestinal obstruction contraindication 126765001
Pregnancy, function contraindication 289908002
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Hepatic Metastases contraindication
Intestinal Ischemic Necrosis contraindication
Severe Granulocytopenia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.32 acidic
pKa2 13.35 acidic
pKa3 8.55 Basic
pKa4 7.39 Basic
pKa5 6.11 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Cytochrome P450 3A4 Enzyme IC50 6 DRUG MATRIX
Substance-K receptor GPCR Ki 6.27 DRUG MATRIX

External reference:

IDSource
4023981 VUID
N0000021986 NUI
D01935 KEGG_DRUG
125317-39-7 SECONDARY_CAS_RN
4020895 VANDF
4023981 VANDF
C0078257 UMLSCUI
CHEBI:480999 CHEBI
GDF PDB_CHEM_ID
CHEMBL553025 ChEMBL_ID
CHEMBL538943 ChEMBL_ID
D000077235 MESH_DESCRIPTOR_UI
DB00361 DRUGBANK_ID
7105 IUPHAR_LIGAND_ID
6054 INN_ID
Q6C979R91Y UNII
5311497 PUBCHEM_CID
114527 RXNORM
2135 MMSL
46388 MMSL
5676 MMSL
d03810 MMSL
004380 NDDF
004381 NDDF
108792008 SNOMEDCT_US
108794009 SNOMEDCT_US
372541004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vinorelbine HUMAN PRESCRIPTION DRUG LABEL 1 25021-204 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Vinorelbine HUMAN PRESCRIPTION DRUG LABEL 1 45963-607 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 19 sections